Cohance Lifesciences Ltd

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live

Cohance Lifesciences announced that the 7th Annual General Meeting(AGM) of the company will be held on 19 September 2025.Powered by Capital Market - Live

Net profit of Cohance Lifesciences declined 21.29% to Rs 42.01 crore in the quarter ended March 2025 as against Rs 53.37 crore during the previous quarter ended March 2024. Sales rose 58.95% to Rs 402.02 crore in the quarter ended March 2025 as against Rs 252.93 crore during the previous quarter ended March 2024. For the full year,net profit declined 10.79% to Rs 267.87 crore in the year ended March 2025 as against Rs 300.28 crore during the previous year ended March 2024. Sales rose 13.91% to Rs 1197.58 crore in the year ended March 2025 as against Rs 1051.35 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales402.02252.93 59 1197.581051.35 14 OPM %18.3029.00 -31.3338.60 - PBDT78.3888.10 -11 421.41460.27 -8 PBT51.6070.85 -27 343.92405.67 -15 NP42.0153.37 -21 267.87300.28 -11 Powered by Capital Market - Live

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection conducted at its API Unit-IV, located at Plot No. A-21, Road No. 10, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, Telangana, India, from 03 March 2025 to 07 March 2025. The inspection was classified as Voluntary Action Indicated (VAI) and indicates the formal closure of the inspection process by the USFDA.Powered by Capital Market - Live

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value of Re 1 each to the eligible shareholders of Cohance Lifesciences (transferor company) in share exchange ratio of 11:295 in terms of the scheme of amalgamation. Powered by Capital Market - Live

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of India (MCA), has approved change of name of the Company from 'Suven Pharmaceuticals' to 'Cohance Lifesciences', with effect from 07 May 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation. The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world said Cohance Executive Chairman, Vivek Sharma.Powered by Capital Market - Live

Suven Pharmaceuticals announced that it has received final approval from the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Government of India, for foreign investment under applicable regulations. This marks the final regulatory clearance required to implement the Scheme of Amalgamation between Cohance Lifesciences and Suven Pharmaceuticals, a transaction previously approved by shareholders and sanctioned by the Hon'ble NCLT, Mumbai Bench. In line with the terms of the approved Scheme of Amalgamation, the merger will take effect from the business opening hours of 1st May 2025, following the satisfaction of all prescribed conditions. The merged company will operate under the name Cohance Lifesciences, subject to applicable regulatory approvals, reflecting a unified platform with expanded CDMO capabilities.Powered by Capital Market - Live

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 May 2025.Powered by Capital Market - Live

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings to the Bank facilities of the Company as under: Long Term Rating - CRISIL A+/Watch Positive (Continues on 'Rating Watch with Positive Implications') Short Term Rating - CRISIL A1+ (Reaffirmed)Powered by Capital Market - Live

Revenue from operations jumped 39.7% to Rs 307.15 crore in Q3 FY25 as compared with Rs 219.82 crore in Q3 FY24. Profit before tax (PBT) stood at Rs 109.73 crore, up 67.6% as compared with Rs 65.47 crore in Q3 FY24. In Q3 FY25, revenue from Suven and Cohance (proforma basis) stood at 6.76 billion, up 40% YoY and Adjusted EBITDA growth of 85% YoY with margins of 38.7% In contract development and manufacturing organization (CDMO) segment, two molecules added this quarter: One molecule advanced to Phase 3 and one directly added to Phase III (laterals addition), increasing total active Phase 3 projects to 15 with 9 molecules. In SpecChem CDMO segment, the company said that it witnessed recovery as expected, following the bottoming out in Q2. On outlook front, the company expects to deliver YoY growth for the combined platform in FY25 on a full year basis, with acceleration expected in FY26. It targets to reach $1 billion revenue, led by an expanding CDMO share, niche tech investments and continued strategic M&A. Vivek Sharma, executive chairman, commented, 'Suven Pharma has reaffirmed its growth trajectory in Q3 FY25 as we had expected. We continue to make BD efforts and remain focused on high-value CDMO offerings and expansion in niche technology platforms in line with our strategic vision. Our investments in ADCs and oligonucleotides with fast underlying market growth position us well for sustained mid and long-term growth. As we gear to deliver our $1 billion revenue guidance with higher CDMO and niche technology share.' V. Prasada Raju, managing director, added: 'We continue to witness a strong momentum in our Pharma CDMO business, with increased RFQ inflows and a robust late-stage pipeline. As our Phase 3 pipeline has expanded now to 15 projects with 9 molecules, gives us comfort on our strategic endeavors moving in the right direction. Our ability to drive innovation with addition of Oligos, deepening our ADC presence, and serve as a trusted partner to global innovators continues to enhance our competitive edge.' Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of the global pharma industry.Powered by Capital Market - Live